Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...

The small cell lung cancer market stands at an inflection point, with ifinatamab deruxtecan representing the vanguard of a ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Lung cancer may be curable, depending on a number of factors, including your age, health, stage of cancer, and how it responds to treatment.

A new report paints a grim outlook for the Massachusetts biotech industry, as venture investment fell 17% in the first half ...

For the first time, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown that it can extend ...

Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma ...

Akeso, a Chinese biotech with a drug positioned to rival Merck’s Keytruda, reported that its lung cancer therapy can improve ...

Survival outcomes for patients with extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation therapy (cTRT) and chemoimmunotherapy (CIT): A population level study ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Non–small cell lung cancer (NSCLC) represents approximately 87% of all lung cancer ...